Greywolf Therapeutics
UK - OxfordBiotechnology
Focus: Greywolf Therapeutics is a UK-based biotech company pioneering ERAP1 and ERAP2 modulation for immuno-oncology, operating at Series B stage with emerging clinical validation in solid tumors and autoimmune disease.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Funding Stage
SERIES B
Total Funding
$131M
Open Jobs
0
About Greywolf Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Greywolf Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Greywolf Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Greywolf Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.